Does the media favor PROK or RANI?

In the previous week, Rani Therapeutics had 5 more articles in the media than ProKidney. MarketBeat recorded 10 mentions for Rani Therapeutics and 5 mentions for ProKidney. Rani Therapeutics' average media sentiment score of 1.03 beat ProKidney's score of 0.37 indicating that Rani Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ProKidney 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Rani Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is KYTX or RANI more profitable?

Kyverna Therapeutics' return on equity of -81.88% beat Rani Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Kyverna Therapeutics N/A -81.88% -64.87% Rani Therapeutics N/A -206.46% -83.95%

Does the media favor KYTX or RANI?

In the previous week, Rani Therapeutics had 3 more articles in the media than Kyverna Therapeutics. MarketBeat recorded 10 mentions for Rani Therapeutics and 7 mentions for Kyverna Therapeutics. Rani Therapeutics' average media sentiment score of 1.03 beat Kyverna Therapeutics' score of 0.38 indicating that Rani Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kyverna Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Rani Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is RANI or CTNM more profitable?

Contineum Therapeutics' return on equity of -27.09% beat Rani Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Rani Therapeutics N/A -206.46% -83.95% Contineum Therapeutics N/A -27.09% -25.64%

Does the media prefer RANI or CTNM?

In the previous week, Rani Therapeutics had 8 more articles in the media than Contineum Therapeutics. MarketBeat recorded 10 mentions for Rani Therapeutics and 2 mentions for Contineum Therapeutics. Rani Therapeutics' average media sentiment score of 1.03 beat Contineum Therapeutics' score of 0.93 indicating that Rani Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rani Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Contineum Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Rani Therapeutics (RANI) Competitors

$0.88 +0.02 (+2.03%)

Closing price 04:00 PM Eastern

Extended Trading

$0.86 -0.02 (-2.30%)

As of 07:44 PM Eastern

Compare

RANI vs. PROK, KYTX, CTNM, AQST, and PRTA

Should you buy Rani Therapeutics stock or one of its competitors? MarketBeat compares Rani Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Rani Therapeutics include ProKidney (PROK), Kyverna Therapeutics (KYTX), Contineum Therapeutics (CTNM), Aquestive Therapeutics (AQST), and Prothena (PRTA). These companies are all part of the "pharmaceutical products" industry.

How does Rani Therapeutics compare to ProKidney?

ProKidney (NASDAQ:PROK) and Rani Therapeutics (NASDAQ:RANI) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, earnings, dividends, analyst recommendations, valuation and media sentiment.

ProKidney has a beta of 1.64, meaning that its stock price is 64% more volatile than the broader market. Comparatively, Rani Therapeutics has a beta of 0.74, meaning that its stock price is 26% less volatile than the broader market.

ProKidney presently has a consensus target price of $7.40, indicating a potential upside of 327.75%. Rani Therapeutics has a consensus target price of $8.75, indicating a potential upside of 899.89%. Given Rani Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Rani Therapeutics is more favorable than ProKidney.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ProKidney	2 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.50
Rani Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Rani Therapeutics has higher revenue and earnings than ProKidney. ProKidney is trading at a lower price-to-earnings ratio than Rani Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ProKidney	$890K	587.15	-$68.99M	-$0.53	N/A
Rani Therapeutics	$1.63M	66.51	-$29.67M	-$0.41	N/A

In the previous week, Rani Therapeutics had 5 more articles in the media than ProKidney. MarketBeat recorded 10 mentions for Rani Therapeutics and 5 mentions for ProKidney. Rani Therapeutics' average media sentiment score of 1.03 beat ProKidney's score of 0.37 indicating that Rani Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ProKidney	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Rani Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

51.6% of ProKidney shares are held by institutional investors. Comparatively, 30.2% of Rani Therapeutics shares are held by institutional investors. 39.8% of ProKidney shares are held by company insiders. Comparatively, 26.7% of Rani Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Rani Therapeutics has a net margin of 0.00% compared to ProKidney's net margin of -8,131.50%. ProKidney's return on equity of 0.00% beat Rani Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ProKidney	-8,131.50%	N/A	-21.39%
Rani Therapeutics	N/A	-206.46%	-83.95%

Summary

Rani Therapeutics beats ProKidney on 8 of the 15 factors compared between the two stocks.

How does Rani Therapeutics compare to Kyverna Therapeutics?

Kyverna Therapeutics (NASDAQ:KYTX) and Rani Therapeutics (NASDAQ:RANI) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, media sentiment, earnings, analyst recommendations, valuation and profitability.

Kyverna Therapeutics has a beta of 1.95, meaning that its share price is 95% more volatile than the broader market. Comparatively, Rani Therapeutics has a beta of 0.74, meaning that its share price is 26% less volatile than the broader market.

18.1% of Kyverna Therapeutics shares are held by institutional investors. Comparatively, 30.2% of Rani Therapeutics shares are held by institutional investors. 17.6% of Kyverna Therapeutics shares are held by insiders. Comparatively, 26.7% of Rani Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Kyverna Therapeutics currently has a consensus price target of $30.00, indicating a potential upside of 283.63%. Rani Therapeutics has a consensus price target of $8.75, indicating a potential upside of 899.89%. Given Rani Therapeutics' higher probable upside, analysts plainly believe Rani Therapeutics is more favorable than Kyverna Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kyverna Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Rani Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Kyverna Therapeutics' return on equity of -81.88% beat Rani Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kyverna Therapeutics	N/A	-81.88%	-64.87%
Rani Therapeutics	N/A	-206.46%	-83.95%

Rani Therapeutics has higher revenue and earnings than Kyverna Therapeutics. Kyverna Therapeutics is trading at a lower price-to-earnings ratio than Rani Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kyverna Therapeutics	N/A	N/A	-$161.31M	-$3.28	N/A
Rani Therapeutics	$1.63M	66.51	-$29.67M	-$0.41	N/A

In the previous week, Rani Therapeutics had 3 more articles in the media than Kyverna Therapeutics. MarketBeat recorded 10 mentions for Rani Therapeutics and 7 mentions for Kyverna Therapeutics. Rani Therapeutics' average media sentiment score of 1.03 beat Kyverna Therapeutics' score of 0.38 indicating that Rani Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kyverna Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Rani Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Rani Therapeutics beats Kyverna Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Rani Therapeutics compare to Contineum Therapeutics?

Rani Therapeutics (NASDAQ:RANI) and Contineum Therapeutics (NASDAQ:CTNM) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, risk, earnings, dividends, institutional ownership, profitability and valuation.

Rani Therapeutics has a beta of 0.74, suggesting that its stock price is 26% less volatile than the broader market. Comparatively, Contineum Therapeutics has a beta of 0.89, suggesting that its stock price is 11% less volatile than the broader market.

Contineum Therapeutics' return on equity of -27.09% beat Rani Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rani Therapeutics	N/A	-206.46%	-83.95%
Contineum Therapeutics	N/A	-27.09%	-25.64%

Rani Therapeutics has higher earnings, but lower revenue than Contineum Therapeutics. Contineum Therapeutics is trading at a lower price-to-earnings ratio than Rani Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rani Therapeutics	$1.63M	66.51	-$29.67M	-$0.41	N/A
Contineum Therapeutics	$50M	9.35	-$59.98M	-$1.95	N/A

In the previous week, Rani Therapeutics had 8 more articles in the media than Contineum Therapeutics. MarketBeat recorded 10 mentions for Rani Therapeutics and 2 mentions for Contineum Therapeutics. Rani Therapeutics' average media sentiment score of 1.03 beat Contineum Therapeutics' score of 0.93 indicating that Rani Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rani Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Contineum Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Rani Therapeutics currently has a consensus target price of $8.75, indicating a potential upside of 899.89%. Contineum Therapeutics has a consensus target price of $20.00, indicating a potential upside of 60.04%. Given Rani Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Rani Therapeutics is more favorable than Contineum Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rani Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Contineum Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

30.2% of Rani Therapeutics shares are owned by institutional investors. 26.7% of Rani Therapeutics shares are owned by insiders. Comparatively, 11.3% of Contineum Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Rani Therapeutics beats Contineum Therapeutics on 9 of the 13 factors compared between the two stocks.

How does Rani Therapeutics compare to Aquestive Therapeutics?

Aquestive Therapeutics (NASDAQ:AQST) and Rani Therapeutics (NASDAQ:RANI) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, media sentiment, valuation, profitability, analyst recommendations, institutional ownership, risk and dividends.

Rani Therapeutics has lower revenue, but higher earnings than Aquestive Therapeutics. Aquestive Therapeutics is trading at a lower price-to-earnings ratio than Rani Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aquestive Therapeutics	$44.54M	11.35	-$83.78M	-$0.61	N/A
Rani Therapeutics	$1.63M	66.51	-$29.67M	-$0.41	N/A

32.5% of Aquestive Therapeutics shares are held by institutional investors. Comparatively, 30.2% of Rani Therapeutics shares are held by institutional investors. 6.8% of Aquestive Therapeutics shares are held by insiders. Comparatively, 26.7% of Rani Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Aquestive Therapeutics has a beta of 1.46, indicating that its stock price is 46% more volatile than the broader market. Comparatively, Rani Therapeutics has a beta of 0.74, indicating that its stock price is 26% less volatile than the broader market.

Aquestive Therapeutics currently has a consensus price target of $8.80, indicating a potential upside of 118.36%. Rani Therapeutics has a consensus price target of $8.75, indicating a potential upside of 899.89%. Given Rani Therapeutics' higher possible upside, analysts clearly believe Rani Therapeutics is more favorable than Aquestive Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aquestive Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	3.00
Rani Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Rani Therapeutics has a net margin of 0.00% compared to Aquestive Therapeutics' net margin of -137.08%. Aquestive Therapeutics' return on equity of 0.00% beat Rani Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aquestive Therapeutics	-137.08%	N/A	-49.33%
Rani Therapeutics	N/A	-206.46%	-83.95%

In the previous week, Rani Therapeutics had 9 more articles in the media than Aquestive Therapeutics. MarketBeat recorded 10 mentions for Rani Therapeutics and 1 mentions for Aquestive Therapeutics. Aquestive Therapeutics' average media sentiment score of 1.89 beat Rani Therapeutics' score of 1.03 indicating that Aquestive Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Aquestive Therapeutics	Very Positive
Rani Therapeutics	Positive

Summary

Aquestive Therapeutics beats Rani Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Rani Therapeutics compare to Prothena?

Rani Therapeutics (NASDAQ:RANI) and Prothena (NASDAQ:PRTA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, media sentiment, profitability, valuation, dividends, analyst recommendations and risk.

Rani Therapeutics has a net margin of 0.00% compared to Prothena's net margin of -260.92%. Prothena's return on equity of -43.44% beat Rani Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rani Therapeutics	N/A	-206.46%	-83.95%
Prothena	-260.92%	-43.44%	-36.87%

Rani Therapeutics has higher earnings, but lower revenue than Prothena. Prothena is trading at a lower price-to-earnings ratio than Rani Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rani Therapeutics	$1.63M	66.51	-$29.67M	-$0.41	N/A
Prothena	$9.68M	48.24	-$244.09M	-$2.82	N/A

In the previous week, Rani Therapeutics had 8 more articles in the media than Prothena. MarketBeat recorded 10 mentions for Rani Therapeutics and 2 mentions for Prothena. Prothena's average media sentiment score of 1.62 beat Rani Therapeutics' score of 1.03 indicating that Prothena is being referred to more favorably in the news media.

Company	Overall Sentiment
Rani Therapeutics	Positive
Prothena	Very Positive

30.2% of Rani Therapeutics shares are owned by institutional investors. Comparatively, 97.1% of Prothena shares are owned by institutional investors. 26.7% of Rani Therapeutics shares are owned by insiders. Comparatively, 10.4% of Prothena shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Rani Therapeutics has a beta of 0.74, meaning that its share price is 26% less volatile than the broader market. Comparatively, Prothena has a beta of -0.25, meaning that its share price is 125% less volatile than the broader market.

Rani Therapeutics presently has a consensus target price of $8.75, suggesting a potential upside of 899.89%. Prothena has a consensus target price of $23.75, suggesting a potential upside of 166.26%. Given Rani Therapeutics' higher possible upside, analysts plainly believe Rani Therapeutics is more favorable than Prothena.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rani Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Prothena	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.63

Summary

Rani Therapeutics beats Prothena on 8 of the 15 factors compared between the two stocks.

Get Rani Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RANI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RANI vs. The Competition

Export

Metric	Rani Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$106.25M	$3.28B	$6.45B	$12.42B
Dividend Yield	N/A	2.33%	2.69%	5.29%
P/E Ratio	N/A	17.93	22.30	24.19
Price / Sales	66.51	324.62	581.44	138.36
Price / Cash	N/A	116.27	42.31	57.88
Price / Book	2.57	6.63	9.84	6.72
Net Income	-$29.67M	$24.20M	$3.57B	$337.19M
7 Day Performance	-7.88%	-3.24%	-1.16%	0.48%
1 Month Performance	-6.90%	0.53%	3.85%	5.07%
1 Year Performance	57.82%	47.24%	27.40%	34.25%

Rani Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RANI Rani Therapeutics	3.4131 of 5 stars	$0.88 +2.0%	$8.75 +899.9%	+54.0%	$106.25M	$1.63M	N/A	110	Positive News Analyst Revision
PROK ProKidney	1.9252 of 5 stars	$1.75 flat	$7.40 +322.9%	+154.7%	$528.35M	$890K	N/A	3	News Coverage
KYTX Kyverna Therapeutics	1.9577 of 5 stars	$8.67 flat	$30.00 +246.0%	+198.1%	$527.09M	N/A	N/A	96	News Coverage Analyst Forecast
CTNM Contineum Therapeutics	3.4458 of 5 stars	$13.86 flat	$20.00 +44.3%	+179.5%	$518.17M	$50M	N/A	31	Gap Up
AQST Aquestive Therapeutics	3.1579 of 5 stars	$4.12 flat	$8.80 +113.6%	+39.9%	$516.85M	$44.54M	N/A	160	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RANI) was last updated on 6/3/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rani Therapeutics (RANI) Competitors

RANI vs. PROK, KYTX, CTNM, AQST, and PRTA

How does Rani Therapeutics compare to ProKidney?

Summary

How does Rani Therapeutics compare to Kyverna Therapeutics?

Summary

How does Rani Therapeutics compare to Contineum Therapeutics?

Summary

How does Rani Therapeutics compare to Aquestive Therapeutics?

Summary

How does Rani Therapeutics compare to Prothena?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RANI vs. The Competition

Rani Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Rani Therapeutics (RANI) Competitors

RANI vs. PROK, KYTX, CTNM, AQST, and PRTA

How does Rani Therapeutics compare to ProKidney?

Which has more risk & volatility, PROK or RANI?

Do analysts recommend PROK or RANI?

Which has higher valuation and earnings, PROK or RANI?

Does the media favor PROK or RANI?

Do insiders & institutionals believe in PROK or RANI?

Is PROK or RANI more profitable?

Summary

How does Rani Therapeutics compare to Kyverna Therapeutics?

Which has more volatility & risk, KYTX or RANI?

Do insiders and institutionals believe in KYTX or RANI?

Do analysts recommend KYTX or RANI?

Is KYTX or RANI more profitable?

Which has preferable earnings & valuation, KYTX or RANI?

Does the media favor KYTX or RANI?

Summary

How does Rani Therapeutics compare to Contineum Therapeutics?

Which has more volatility and risk, RANI or CTNM?

Is RANI or CTNM more profitable?

Which has higher valuation & earnings, RANI or CTNM?

Does the media prefer RANI or CTNM?

Do analysts recommend RANI or CTNM?

Do insiders & institutionals believe in RANI or CTNM?

Summary

How does Rani Therapeutics compare to Aquestive Therapeutics?

Which has stronger earnings & valuation, AQST or RANI?

Do institutionals and insiders believe in AQST or RANI?

Which has more risk and volatility, AQST or RANI?

Do analysts rate AQST or RANI?

Is AQST or RANI more profitable?

Does the media favor AQST or RANI?

Summary

How does Rani Therapeutics compare to Prothena?

Is RANI or PRTA more profitable?

Which has better earnings & valuation, RANI or PRTA?

Does the media prefer RANI or PRTA?

Do insiders and institutionals have more ownership in RANI or PRTA?

Which has more risk and volatility, RANI or PRTA?

Do analysts rate RANI or PRTA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RANI vs. The Competition

Rani Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools